Home Overview of Products & Technology

ATIR (Allodepleted T-cell ImmunotheRapeutics) is designed to support the patient’s newly transplanted immune system before it becomes fully functional. In ATIR, T-cells causing Graft-versus-Host-Disease (GVHD) have been depleted, while T-cells protective against tumor cells and infections have been retained. This provides physicians with the opportunity to infuse potent T-cells with minimal risk of causing potential lethal severe GVHD. ATIR therefore addresses one of the biggest challenges of using haploidentical family members as stem cell donors for those patients that would otherwise not find a matching donor in time.

The Company’s lead product, ATIR101, addresses key risks and limitations of HSCT in blood cancers, specifically GVHD and cancer relapse. ATIR101 is a cellular product for infusion. It consist of donor lymphocytes (immune cells), specifically manufactured for each individual patient from a healthy, haploidentical stem cell donor.

Using the Company’s proprietary selective cytotoxic compound, TH9402, those T-cells which attack the patient, causing Graft-versus-Host Disease (GVHD), are depleted. The full immune repertoire of other donor immune cells, including immunological memory, is retained in the final product.

ATIR Manufacturing Process

Kiadis Pharma has established a GMP-compliant, manufacturing process and has received an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the European Medicines Agency (EMA).

Print